Drug Trial Radar · NCT05375903
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
Last checked: Nov 20, 2026Latest source record: Jan 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
51
Actual
Start
Jun 1, 2022
Primary completion
Jan 9, 2026
Study completion Jan 9, 2026
Sponsor
- Lead sponsor
- UroGen Pharma Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 17, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to evaluate the safety and determine the recommended Phase 2 dose (RP2D) of UGN-301 (zalifrelimab) administered intravesically as monotherapy and in combination with other agents in patients with recurrent NMIBC.
Conditions
- Non-muscle Invasive Bladder Cancer
- NMIBC
- Carcinoma in Situ of Bladder
- Bladder Cancer
- Urothelial Carcinoma Bladder
- Urothelial Carcinoma Recurrent
Interventions
UGN-301Drug
Induction Period: Intravesical administration once weekly for 6 weeks. Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment).
UGN-201Drug
Induction Period: Intravesical administration once weekly for 6 weeks. Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment).
GemcitabineDrug
Induction Period: Intravesical administration once weekly for 6 weeks. Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicities (DLTs) and treatment-emergent adverse events (TEAEs)Time frame: Up to 15 months
- Concentration of UGN-301 in blood and urineTime frame: 6 weeks
- Complete response rate (CRR)Time frame: 3 months
- Recurrence-free survival (RFS) rateTime frame: 3 months
Locations
13 sites in 3 countries. Site status is shown where the registry gives one.
Arkansas Urology
Little Rock, Arkansas
UCLA - University of California
Los Angeles, California
Florida Urology Partners, LLC
Tampa, Florida
Johns Hopkins University
Baltimore, Maryland
Manhattan Medical Research
New York, New York
Clinical Research Solutions
Middleburg Heights, Ohio
Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania
I.R.C.C.S. Ospedale San Raffaele
Milan, Italy
National Tumor Institute Fondazione G. Pascale
Naples, Italy
Istituto Oncologico Veneto
Padova, Italy
NEXT Oncology IOB- Hospital Quironsalud Barcelona
Barcelona, Spain
Hospital Clinic de Barcelona Instituto Clinic de Nefrologia y Urologia (ICNU)
Barcelona, Spain
NEXT Oncology- Hospital Quironsalud Mardrid
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.